I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Share this page: More
ANBL1221, A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864, IND# 61010) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408, IND# 4308) in Children with Refractory, Relapsed or Progressive Neuroblastoma
Johns Hopkins Kimmel Cancer Center in Baltimore
This Phase II study is designed to compare the response rates (RR) and progression free survival (PFS) for patients with refractory, relapsed or progressive neuroblastoma receiving temsirolimus or ch14.18 in combination with irinotecan and temozolomide.
Inclusion Criteria:1)all ages2)must have had histologic verification of neuroblastoma or ganglioneuroblastoma or demonstration of neuroblastoma cells in the bone marrow with elevated urinary catecholamines (ie, greater than 2 x ULN), at the time of initial diagnosis.3)Patients must have ONE of the following:4)First episode of recurrent disease following completion of aggressive multi-drug frontline therapy.5)First episode of progressive disease during aggressive multi-drug frontline therapy.6)Primary resistant/refractory disease detected at the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol (examples include A3973, ANBL0532, ANBL09P1, etc.).7)Patients must have at least ONE of the following:8)Measurable tumor on MRI, CT scan obtained within 3 weeks prior to study entry. Measurable is defined as ï¿½ 10 mm in at least one dimension on spiral/helical CT that is MIBG avid or demonstrates increased FDG uptake on PET scan.9)MIBG scan obtained within 3 weeks prior to study entry with positive uptake at a minimum of one site. This site must represent disease recurrence after completion of therapy, progressive disease on therapy, or refractory disease during induction.10)Patients with resistant/refractory soft tissue disease that is not MIBG avid or does not demonstrate increased FDG uptake on PET scan must undergo biopsy to document the presence of viable neuroblastoma. Biopsy is not required for patients who have new site of soft tissue disease (radiographic evidence of disease progression) regardless of whether progression occurs while receiving therapy or after completion of therapy.11)Patients must have a performance status corresponding to ECOG scores of 0, 1 or 2. Use Karnofsky for patients greater than 16 years of age and Lansky for patients 16 years of age. 12)Patients must have received frontline therapy (including surgery, chemotherapy, autologous SCT +/- MIBG, immunotherapy, radiotherapy, and retinoids) but may NOT have received second line chemotherapy for resistant/refractory, relapsed disease or progressive disease.13)At least 14 days must have elapsed since completion of myelosuppressive therapy.14)At least 7 days must have elapsed since the completion of therapy with a non-myelosuppressive biologic agent or retinoid.15)No interim time prior to study entry is required following prior RT for non-target lesions. However, patients must not have received radiation for a minimum of 4 weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response. Lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma. Palliative radiation is allowed to sites that will not be used to measure response during this study.16)Patients are eligible 6 weeks after autologous stem cell transplants or stem cell infusions as long as hematologic and other eligibility criteria have been met.17)Patients are eligible 6 weeks after therapeutic 131I-MIBG provided that all other eligibility criteria are met.18)Subjects who have previously received anti-GD2 monoclonal antibodies for biologic therapy or for tumor imaging are eligible unless they have had progressive disease while receiving prior anti-GD2 therapy. Subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads, but no other form of anti-GD2 monoclonal antibody, are eligible.19)concomitant therapy restrictions for patients during treatment20)Patients must not have received long-acting myeloid growth factors (eg, Neulasta) within 14 days of entry on this study. Seven days must have elapsed since administration of a short-acting myeloid growth factor.21)Peripheral absolute neutrophil count (ANC)750/Î¼L22)Platelet count 75,000/Î¼L (transfusion independent)23)Patients known to have bone marrow involvement with neuroblastoma are eligible provided that minimum ANC and platelet count criteria are met but are not evaluable for hematological toxicity.24)Creatinine clearance or estimated radioisotope GFR 70 mL/min/1.73 m2 or a serum creatinine upper limit of normal25)Total bilirubin 1.5 x ULN for age AND SGPT (ALT) 5.0 x ULN for age (225 U/L). For the purpose of this study, the ULN for SGPT is 45 U/L.25)Patients with a history of CNS disease must have no clinical or radiological evidence of CNS disease at the time of study enrollment26)Patients with seizure disorders may be enrolled if seizures are well controlled on anti-convulsants26)No evidence of dyspnea at rest, no exercise intolerance, no chronic oxygen requirement, and room air pulse oximetry greater than 94% if there is a clinical indication for pulse oximetry. Normal pulmonary function tests in patients who are capable of cooperating with testing (including DLCO) are required if there is a clinical indication for determination. For patients who do not have respiratory symptoms, full PFTs are NOT required.Exclusion Criteria:1)Men and women of childbearing potential and their partners must agree to use adequate contraception while enrolled on this study. Based on the established teratogenic potential of alkylating agents and temsirolimus, pregnant women will be excluded from this study. Because of potential risks to breastfed infants due to drug metabolites that could be excreted in breast milk, female patients who are lactating must agree to stop breastfeeding or will otherwise be excluded from this study. Females of childbearing potential must have a negative pregnancy test to be eligible for this study.2)Patients with elevated catecholamines (ie, greater than 2 x ULN) only or bone marrow disease only are NOT eligible for this study.3)Patients must have been off pharmacologic doses of systemic steroids for at least 7 days prior to enrollment. Patients who require or are likely to require pharmacologic doses of systemic corticosteroids while receiving treatment on this study are ineligible. The only exception is for patients known to require 2 mg/kg or less of hydrocortisone (or an equivalent dose of an alternative corticosteroid) as premedication for blood product administration in order to avoid allergic transfusion reactions. The use of conventional doses of inhaled steroids for the treatment of asthma is permitted, as is the use of physiologic doses of steroids for patients with known adrenal insufficiency.4)Patients must not have received enzyme-inducing anticonvulsants including phenytoin, phenobarbital, valproic acid, or carbamazepine for at least 7 days prior to study enrollment. Patients receiving non-enzyme inducing anticonvulsants such as gabapentin or levetiracetam will be eligible.5)Patients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastoma.6)Patients with symptoms of congestive heart failure are not eligible.7)Patients must not have ï¿½ Grade 2 diarrhea8)Patients must not have uncontrolled infection.9)Patients who have received prior therapy with an mTOR inhibitor in combination with cytotoxic chemotherapy are not eligible.10)Patients with a history of significant allergic reactions attributed to compounds of similar chemical or biologic composition to temsirolimus are not eligible.11)Patients with a history of Grade 4 allergic reactions to anti-GD2 antibodies or reactions that required discontinuation of the anti-GD2 therapy are not eligible.12)Patients with a significant intercurrent illness (any ongoing serious medical problem unrelated to cancer or its treatment) that is not covered by the detailed exclusion criteria and that is expected to interfere with the action of study agents or to significantly increase the severity of the toxicities experienced from study treatment are not eligible.13)Patien
Experimental: Regimen A Irinotecan/Temozolomide/ TemsirolimusExperimental: Regimen B Irinotecan/Temozolomide/Chimeric 14.18 Antibody/GM-CSF/SargramostimLong-term survival rates for children with high-risk neuroblastoma remain poor. In addition, survivors experience significant immediate and late toxicities limiting further dose intensification with conventional chemotherapy agents. Novel biological therapies are therefore needed. This "Pick the Winner" Phase II study is designed to compare the response rates (RR) and progression free survival (PFS) for patients with refractory, relapsed or progressive neuroblastoma receiving temsirolimus or ch14.18 in combination with irinotecan and temozolomide. The irinotecan and temozolomide combination has shown activity against relapsed/refractory neuroblastoma. Furthermore, its favorable toxicity profile makes it an attractive backbone chemotherapy regimen for assessment of the contribution of novel molecularly targeted agents. Neuroblastoma cells have shown sensitivity to mTOR inhibitors both in vitro and in vivo. mTOR inhibitors have also been shown to have synergistic or additive effects when combined with several conventional chemotherapeutic drugs, including those frequently used in the treatment of neuroblastoma. The combination of irinotecan and temozolomide with the mTOR inhibitor temsirolimus is well tolerated in children, and this 3-drug regimen will comprise one arm of this study. The second arm will include irinotecan and temozolomide in combination with the chimeric anti-GD2 antibody ch14.18. The disialoganglioside GD2 is expressed on neuroblastoma cells, but its expression in normal human tissues is limited. A randomized Phase III study (COG ANBL0032) compared the event free survival of patients with high risk neuroblastoma treated with ch14.18 combined with GM-CSF, interleukin 2 and isotretinoin to that of patients treated with isotretinoin alone as post-consolidation therapy. Randomization was stopped early because of superior survival associated with the antibody-containing regimen. Preclinical studies of anti-GD2 antibodies combined with cytotoxic chemotherapy have shown synergistic or additive effects on neuroblastoma cells. These data support evaluation of the addition of ch14.18 to chemotherapy for children with refractory, relapsed or progressive neuroblastoma. The agent selected for further study as a result of this trial will be integrated into frontline induction therapy for future patients with high-risk neuroblastoma.
08/17/2017 05:03 AM